Daniel O'Day is the CEO of Gilead Sciences, a top player in the pharmaceutical industry known for its focus on treatments for serious diseases like HIV and hepatitis. He took the reins at Gilead on March 1, 2019, after a...

Daniel O'Day is the CEO of Gilead Sciences, a top player in the pharmaceutical industry known for its focus on treatments for serious diseases like HIV and hepatitis. He took the reins at Gilead on March 1, 2019, after a long and successful career at Roche Pharmaceuticals, where he spent over 30 years. With a strong background in biology from Georgetown University and an MBA from Columbia Business School, Daniel combines science with business savvy. Under his leadership, Gilead has made significant strides in health care innovation. In 2023, his compensation was over $22 million, mostly coming from performance-based stock awards that reflect how well the company is doing. He holds substantial shares in Gilead, worth about $35 million, which shows he's invested in the company's future. Daniel is all about aligning executive pay with company performance, making sure that both he and the shareholders benefit as Gilead grows. He has also demonstrated a commitment to innovation and tackling tough health challenges, positioning Gilead as a leader in the pharmaceutical landscape.